

NRG Oncology Presentation Schedule

Oral, Rapid Oral, Poster, and Educational Presentations

MAY 29 - JUNE 2, 2026 | MCCORMICK PLACE, CHICAGO, IL

Advancing Research. Improving Lives.™

Disease Site & Study #	Friday, May 29, 2026	Time/Location
Gynecologic NRG-GY018	<p>Title: <i>Updated overall survival analysis and examination of subsequent therapy in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG-GY018 trial.</i></p> <p>Presenter: Ramez Nassef Eskander, MD</p> <p>Abstract 5502</p>	<p>Location: S100bc Live Stream Session: Gynecologic Cancer Time: 2:57-3:09 PM CDT Oral Session</p>
Disease Site & Study #	Saturday, May 30, 2026	Time/Location
Gastrointestinal NRG-GI008	<p>Title: <i>NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA).</i></p> <p>Presenter: Arvind Dasari, MD</p> <p>Abstract TPS3686 Poster Bd 446a</p>	<p>Location: Hall A - Posters and Exhibits Session: Gastrointestinal Cancer-Colorectal and Anal Time: 9:00 AM-12:00 PM CDT Poster Session</p>
Head & Neck NRG-HN006	<p>Title: <i>NRG-HN006: Randomized phase II/III trial of sentinel lymph node biopsy versus elective neck dissection for early-stage oral cavity cancer.</i></p> <p>Presenter: Stephen Y Lai, MD</p> <p>Abstract TPS6138 Poster Bd 588b</p>	<p>Location: Hall A - Posters and Exhibits Session: Head and Neck Cancer Time: 1:30 PM-4:30 PM CDT Poster Session</p>
Head & Neck NRG-HN015	<p>Title: <i>NRG-HN015: A phase II randomized trial of neoadjuvant chemotherapy or chemo-immunotherapy in patients with recurrent/persistent PD-L1-positive squamous cell carcinoma of the head and neck undergoing salvage surgery.</i></p> <p>Presenter: Nabil F Saba, MD</p> <p>Abstract TPS6128 Poster Bd 583b</p>	<p>Location: Hall A - Posters and Exhibits Session: Head and Neck Cancer Time: 1:30 PM-4:30 PM CDT Poster Session</p>
Genitourinary-Prostate NRG-RTOG 9202 NRG-RTOG 9413 NRG-RTOG 9902 NRG-RTOG 0521	<p>Title: <i>Clinico-transcriptomic risk stratification to guide abiraterone treatment intensification in high-risk prostate cancer: A combined analysis of NRG/RTOG 9202, 9413, 9902, and 0521.</i></p> <p>Presenter: Krishnan R Patel, MD</p> <p>Abstract 5000</p>	<p>Location: Hall D1 Live Stream Session: Genitourinary Cancer-Prostate, Testicular, and Penile Time: 3:00-3:12 PM CDT Oral Session</p>
Disease Site & Study #	Sunday, May 31, 2026	Time/Location

Genitourinary-Prostate NRG-RTOG 0521	<p>Title: <i>Spatial transcriptomics-guided pathology biomarker as a predictor of benefit of adjuvant docetaxel in high-risk localized prostate cancer: NRG/RTOG 0521 (NCT00288080).</i></p> <p>Presenter: Sebastian R. Medina, MSc 1st Author: Mamunur Rahaman, PhD</p> <p>Abstract 5111 Poster Bd 206</p>	<p>Location: Hall A - Posters and Exhibits Session: Genitourinary Cancer-Prostate, Testicular, and Penile Time: 9:00 AM-12:00 PM CDT Poster Session</p>
---	--	---

Disease Site & Study #	Monday, June 1, 2026	Time/Location
------------------------	----------------------	---------------

Gynecologic NRG-GY036	<p>Title: <i>NRG-GY036: A phase III trial of one vs. two years of maintenance olaparib, with or without bevacizumab, in patients with BRCA1/2-mutated or homologous recombination deficient (HRD+) ovarian cancer following response to first line platinum-based chemotherapy.</i></p> <p>Presenter: Ying L Liu, MD, MPH</p> <p>Abstract TPS5634 Poster Bd 297a</p>	<p>Location: Hall A - Posters and Exhibits Session: Gynecologic Cancer Time: 9:00-12:00 PM CDT Poster Session</p>
--------------------------	---	---

Gynecologic NRG-GY037	<p>Title: <i>NRG-GY037: A phase III randomized trial of induction chemotherapy and pembrolizumab followed by chemoradiation and pembrolizumab maintenance versus standard chemoradiation and pembrolizumab maintenance in high-risk locally advanced cervical cancer.</i></p> <p>Presenter: Jyoti Mayadev, MD</p> <p>Abstract TPS5632 Poster Bd 296a</p>	<p>Location: Hall A - Posters and Exhibits Session: Gynecologic Cancer Time: 9:00-12:00 PM CDT Poster Session</p>
--------------------------	---	---

Breast NRG-BR009	<p>Title: <i>A phase III trial evaluating addition of adjuvant chemotherapy to ovarian function suppression + endocrine therapy in premenopausal women with pN0-1, HR+/HER2- breast cancer and Oncotype recurrence score ≤ 25 (OFSET): NRG-BR009.</i></p> <p>Presenter: Eleftherios P Mamounas, MD</p> <p>Abstract TPS650 Poster Bd 131a</p>	<p>Location: Hall A - Posters and Exhibits Session: Breast Cancer-Local/Regional/Adjuvant Time: 1:30 PM-4:30 PM CDT Poster Session</p>
---------------------	---	--

Disease Site & Study #	Tuesday, June 2, 2026	Time/Location
------------------------	-----------------------	---------------

Disease Site & Study #	The following presentations include NRG author/investigators from NCTN-sponsored federal trials, and NSABP-RTOG-GOG Foundation studies	Time/Location
Gastrointestinal NSABP FC-13	<p>Title: <i>NSABP FC-13 (EMPIRE): A phase II platform study of cemiplimab monotherapy or cemiplimab-based combinations in patients with colorectal cancer and minimal residual disease (MRD) after definitive therapy.</i></p> <p>Presenter: Anwaar Saeed, MD</p> <p>Abstract TPS3685 Poster Bd 445b</p> <p><u>NRG Author: Anwaar Saeed, MD</u></p>	<p>Location: Hall A - Posters and Exhibits Session: Poster Session - Gastrointestinal Cancer—Colorectal and Anal Date/Time: May 30, 2026, 9:00 AM-12:00 PM CDT Poster Session</p>

<p>Breast NSABP B-28</p>	<p>Title: <i>AI-driven risk stratification for distant recurrence in node-positive HR+/HER2- early breast cancer: Independent validation in the NSABP B-28 trial.</i></p> <p>Presenter: Priya Rastogi, MD</p> <p>Abstract 558 Poster Bd 43</p> <p><u>NRG Author: Priya Rastogi, MD</u></p>	<p>Location: Hall A - Posters and Exhibits</p> <p>Session: Breast Cancer-Local/Regional/Adjuvant</p> <p>Date/Time: June 1, 2026, 1:30 PM-4:30 PM CDT</p> <p>Poster Session</p>
------------------------------	---	--